What is Medicus Pharma Ltd's earnings per share (EPS)?

Medicus Pharma Ltd (MDCXW) reported diluted earnings per share of $-1.16 for fiscal year 2024. This represents a 24.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Medicus Pharma Ltd Financials

MDCXW

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Medicus Pharma Ltd (MDCXW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Medicus Pharma Ltd passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.92x

For every $1 of reported earnings, Medicus Pharma Ltd generates $0.92 in operating cash flow (-$10.2M OCF vs -$11.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$11.2M

YoY-109.9%

Medicus Pharma Ltd reported -$11.2M in net income in fiscal year 2024. This represents a decrease of 109.9% from the prior year.

EPS (Diluted)

$-1.16

YoY+24.2%

Medicus Pharma Ltd earned $-1.16 per diluted share (EPS) in fiscal year 2024. This represents an increase of 24.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$4.2M

YoY+142.2%

Medicus Pharma Ltd held $4.2M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

12M

YoY+46.3%

Medicus Pharma Ltd had 12M shares outstanding in fiscal year 2024. This represents an increase of 46.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-355.9%

YoY+122.3pp

Medicus Pharma Ltd's ROE was -355.9% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 122.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$3.5M

YoY+1722.4%

Medicus Pharma Ltd invested $3.5M in research and development in fiscal year 2024. This represents an increase of 1722.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

MDCXW Income Statement

Metric	FY24	FY23
Revenue	N/A	N/A
Cost of Revenue	N/A	N/A
Gross Profit	N/A	N/A
R&D Expenses	$3.5M+1722.4%	$194K
SG&A Expenses	$7.7M+68.7%	$4.5M
Operating Income	-$11.2M-136.4%	-$4.7M
Interest Expense	N/A	N/A
Income Tax	$0	$0
Net Income	-$11.2M-109.9%	-$5.3M
EPS (Diluted)	$-1.16+24.2%	$-1.53

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.7M+17.0%	$1.4M-28.2%	$2.0M	N/A	$564K-55.8%	$1.3M+297.4%	$321K	N/A
SG&A Expenses	$5-100.0%	$4.6M+46.7%	$3.1M	N/A	$1.8M-22.2%	$2.3M+64.3%	$1.4M	N/A
Operating Income	-$15+100.0%	-$6.0M-17.4%	-$5.1M	N/A	-$2.3M+34.3%	-$3.6M-108.1%	-$1.7M	N/A
Interest Expense	$12K-71.1%	$40K	N/A	N/A	$56K+170.2%	-$79K	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$20.9M-239.0%	-$6.2M-21.0%	-$5.1M	N/A	-$2.3M+37.3%	-$3.6M-112.8%	-$1.7M	N/A
EPS (Diluted)	$-1.12-160.5%	$-0.43-2.4%	$-0.42	N/A	$-0.24+45.5%	$-0.44-109.5%	$-0.21	N/A

MDCXW Balance Sheet

Metric	FY24	FY23
Total Assets	$5.6M+198.3%	$1.9M
Current Assets	$5.4M+184.1%	$1.9M
Cash & Equivalents	$4.2M+142.2%	$1.7M
Inventory	N/A	N/A
Accounts Receivable	N/A	N/A
Goodwill	N/A	N/A
Total Liabilities	$2.5M+221.4%	$782K
Current Liabilities	$2.3M+195.1%	$782K
Long-Term Debt	N/A	N/A
Total Equity	$3.1M+182.0%	$1.1M
Retained Earnings	-$28.9M-62.9%	-$17.7M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$10.0M-16.4%	$11.9M+110.9%	$5.7M+0.2%	$5.6M	N/A	N/A	N/A	$1.9M
Current Assets	$9.8M-11.1%	$11.0M+116.1%	$5.1M-5.4%	$5.4M	N/A	N/A	N/A	$1.9M
Cash & Equivalents	$8.7M-10.4%	$9.7M+142.8%	$4.0M-4.4%	$4.2M-21.5%	$5.3M-36.9%	$8.4M+1450.2%	$542K-68.5%	$1.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.8M+24.1%	$8.7M+147.4%	$3.5M+39.7%	$2.5M	N/A	N/A	N/A	$782K
Current Liabilities	$10.7M+24.7%	$8.5M+156.1%	$3.3M+44.6%	$2.3M	N/A	N/A	N/A	$782K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$910K-128.0%	$3.2M+51.3%	$2.1M-31.5%	$3.1M-34.6%	$4.8M-32.2%	$7.1M+1363.2%	-$560K-150.4%	$1.1M
Retained Earnings	-$5+100.0%	-$40.2M-18.2%	-$34.0M-17.7%	-$28.9M	N/A	N/A	N/A	-$17.7M

MDCXW Cash Flow Statement

Metric	FY24	FY23
Operating Cash Flow	-$10.2M-146.4%	-$4.2M
Capital Expenditures	N/A	N/A
Free Cash Flow	N/A	N/A
Investing Cash Flow	N/A	N/A
Financing Cash Flow	$12.7M+126.2%	$5.6M
Dividends Paid	N/A	N/A
Share Buybacks	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$6.8M-23.6%	-$5.5M-38.8%	-$3.9M-23.5%	-$3.2M-2.9%	-$3.1M-11.7%	-$2.8M-135.9%	-$1.2M	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$10.4M-7.0%	$11.2M+196.8%	$3.8M+83.4%	$2.0M	$0-100.0%	$10.6M	$0	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MDCXW Financial Ratios

Metric	FY24	FY23
Gross Margin	N/A	N/A
Operating Margin	N/A	N/A
Net Margin	N/A	N/A
Return on Equity	-355.9%+122.3pp	-478.2%
Return on Assets	-197.6%+83.2pp	-280.8%
Current Ratio	2.33-0.1	2.42
Debt-to-Equity	0.80+0.1	0.70
FCF Margin	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-190.1%+47.5pp	-237.6%	N/A	-47.5%+3.8pp	-51.4%	N/A	N/A
Return on Assets	-209.8%-158.1pp	-51.7%+38.4pp	-90.2%	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.92-0.4	1.29-0.2	1.53-0.8	2.33	N/A	N/A	N/A	2.42
Debt-to-Equity	-11.85-14.5	2.67+1.0	1.63+0.8	0.80	N/A	N/A	N/A	0.70
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is Medicus Pharma Ltd profitable?

No, Medicus Pharma Ltd (MDCXW) reported a net income of -$11.2M in fiscal year 2024.

What is Medicus Pharma Ltd's return on equity (ROE)?

Medicus Pharma Ltd (MDCXW) has a return on equity of -355.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Medicus Pharma Ltd's operating cash flow?

Medicus Pharma Ltd (MDCXW) generated -$10.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Medicus Pharma Ltd's total assets?

Medicus Pharma Ltd (MDCXW) had $5.6M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Medicus Pharma Ltd spend on research and development?

Medicus Pharma Ltd (MDCXW) invested $3.5M in research and development during fiscal year 2024.

How many shares does Medicus Pharma Ltd have outstanding?

Medicus Pharma Ltd (MDCXW) had 12M shares outstanding as of fiscal year 2024.

What is Medicus Pharma Ltd's current ratio?

Medicus Pharma Ltd (MDCXW) had a current ratio of 2.33 as of fiscal year 2024, which is generally considered healthy.

What is Medicus Pharma Ltd's debt-to-equity ratio?

Medicus Pharma Ltd (MDCXW) had a debt-to-equity ratio of 0.80 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Medicus Pharma Ltd's return on assets (ROA)?

Medicus Pharma Ltd (MDCXW) had a return on assets of -197.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Medicus Pharma Ltd's cash runway?

Based on fiscal year 2024 data, Medicus Pharma Ltd (MDCXW) had $4.2M in cash against an annual operating cash burn of $10.2M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Medicus Pharma Ltd's Piotroski F-Score?

Medicus Pharma Ltd (MDCXW) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Medicus Pharma Ltd's earnings high quality?

Medicus Pharma Ltd (MDCXW) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.